Patients with ANCA-associated vasculitis remain 'soaked in steroids' despite new therapies

DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for patients with ANCA-associated vasculitis,” according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

Related Keywords

Massachusetts ,United States ,Byrob Volansky ,John Stone ,Shenaz Bagha ,Edwarda Fox ,Amgen ,Harvard Medical School ,Genentech ,Associated Vasculitis ,How Have New Therapies Changed Induction ,Clinical Rheumatology East ,Massachusetts General Hospital ,New England Journal ,